Philippines - English - FDA (Food And Drug Administration)

multicare pharmaceuticals phils. inc. - traxenamic acid - solution for injection - 100mg/ ml (500mg/ 5ml)

United States - English - NLM (National Library of Medicine)

micro labs limited - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. - in patients with active intravascular clotting [see warnings and precautions ( 5.1 )] . - in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions ( 5.4 )] . risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tranexamic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: macrogol 8000; vanillin; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; purified talc; povidone; basic butylated methacrylate copolymer - oral administration hereditary angioneurotic oedema. short term use in the treatment of hyphaema and in patients with established coagulopathies who are undergoing minor surgery. menorrhagia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

United States - English - NLM (National Library of Medicine)

prasco laboratories - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies (14) ]. prior to prescribing tranexamic acid tablets, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe tranexamic acid tablets to women who are - using combination hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g.,